{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:31:38Z","timestamp":1791304298682,"version":"4.3.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Amid an international pandemic and a worsening mental health crisis, ketamine-assisted therapy is emerging as a promising solution for those deemed \u201ctreatment resistant.\u201d Post-traumatic stress disorder (PTSD) and depression are on the rise, with accelerating direct (e.g., burden of suffering) and indirect (e.g., disability\/role impairment and impact on family) costs. Psychedelic-assisted therapies show significant promise in the treatment of a number of clinically challenging conditions, including depression, anxiety, PTSD, addiction, and end-of-life distress. Ketamine is currently the only safe, effective and legal widely available psychedelic-like medicine. To address the echo pandemic of health care provider distress, a multi-disciplinary team was charged with developing a ketamine-assisted psychotherapy program, delivered in a community of practice (CoP) group model and evaluated in a quality improvement framework. Program evaluation occurred through mixed methods. Quantitative mental health assessments included the PHQ-9 for depression, the PCL-5 for PTSD, GAD-7 for generalized anxiety disorder (GAD), and B-IPF for work\/life functionality. Participant narrative feedback was collected to evaluate outcomes and for quality improvement purposes. Mean mental health scores were collected across three cohorts, totaling 94 patients. The mean aggregate scores of participants meeting the mental health assessment cut-off criteria (screening positive) were analyzed to assess clinical significance. Mean aggregate results comparing baseline vs. outcome measures (measured within 1\u20132 weeks after completion of the 12-week program) were clinically significant, demonstrating significant improvements in depression, post-traumatic stress disorder, generalized anxiety disorder and work\/life functionality. In summary, 91% saw improvements in generalized anxiety, 79% saw improvements in depression, 86% of those who screened positive for PTSD now screen negative, and 92% had significant life\/work functionality improvements. Qualitative feedback was overwhelmingly positive, with several unsolicited self-reports of transformation. Participant and team feedback enables the program to continue improving with each iteration. Results speak to the effectiveness of ketamine for psychedelic-assisted therapy, supported by a CoP framework. Outcomes are relevant for mental health programming, education and healthcare policy.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.803279","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:39:59Z","timestamp":1648820399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression"],"prefix":"10.3389","volume":"12","author":[{"given":"Shannon","family":"Dames","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Kryskow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crosbie","family":"Watler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1001\/jamanetworkopen.2020.3976","article-title":"Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019","volume":"3","author":"Lai","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B2","volume-title":"Root Strength: A Health and Care Professionals' Guide to Minimizing Stress and Maximizing Thriving","author":"Dames","year":"2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2014.07.046","article-title":"Faster, better, stronger: towards new antidepressant therapeutic strategies","volume":"753","author":"O'Leary","year":"2015","journal-title":"Eur J Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0140-6736(18)31612-X","article-title":"The lancet commission on global mental health and sustainable development","volume":"10157","author":"Patel","year":"2018","journal-title":"Lancet."},{"key":"B5","unstructured":"2021"},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1027\/2151-2604\/a000176","article-title":"Antidepressants and the placebo effect","volume":"222","author":"Kirsch","year":"2014","journal-title":"Z Psychol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1503\/cmaj.141124","article-title":"Psychedelic medicine: a re-emerging therapeutic paradigm","volume":"187","author":"Tupper","year":"2015","journal-title":"CMAJ Can Med Assoc J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic post-traumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond","year":"2014","journal-title":"Psychopharmacology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/0253-7176.127258","article-title":"Acute antidepressant effects of intramuscular versus intravenous ketamine","volume":"36","author":"Chilukuri","year":"2014","journal-title":"Indian J Psychol Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/npp.2017.194","article-title":"Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial","volume":"43","author":"Taylor","year":"2018","journal-title":"Neuropsychopharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am J Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front Psychiatry."},{"key":"B18","volume-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Place of publication not identified: Wolters Kluwer Health","author":"Briggs","year":"2016"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511815355","volume-title":"Situated Learning: Legitimate Peripheral Participation.","author":"Lave","year":"1991"},{"key":"B20","unstructured":"Introduction to Communities of Practice: A Brief Overview of the Concept and it's Uses\n            Wenger-TreynerE\n            Wenger-TreynerB"},{"key":"B21","first-page":"184","article-title":"A theory of therapy, personality, and interpersonal relationships: as developed in the client-centered framework. In: Koch S, editor","volume-title":"Psychology: A Study of a Science. Formulations of the Person and the Social Context","author":"Rogers","year":"1959"},{"key":"B22","volume-title":"Health, Stress and Coping","author":"Antonovsky","year":"1979"},{"key":"B23","volume-title":"Client-Centered Therapy","author":"Rogers","year":"1956"},{"key":"B24","volume-title":"The Polyvagal Theory: Neurophysiological Foundations of Emotions, Attachment, Communication, and Self-regulation","author":"Porges","year":"2011"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2470547019842545","DOI":"10.1177\/2470547019842545","article-title":"Structural plasticity induced by ketamine in human dopaminergic neurons as mechanism relevant for treatment-resistant depression","volume":"3","author":"Collo","year":"2019","journal-title":"Chronic Stress"}],"updated-by":[{"DOI":"10.3389\/fpsyt.2022.962882","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000}}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.803279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T05:01:12Z","timestamp":1658206872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.803279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":25,"alternative-id":["10.3389\/fpsyt.2021.803279"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.803279","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"article-number":"803279"}}